News
Public · Published
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Merck began the ENHANCE-3 Phase 3 trial of Ohtuvayre (ensifentrine) to prevent COPD flare-ups in adults on standard care with a history of flare-ups. Enrollment has started in the United States, with about 2,136 patients planned across 28 countries.
Published:
Updated:
What happened
Merck began the ENHANCE-3 Phase 3 trial of Ohtuvayre (ensifentrine) to prevent COPD flare-ups in adults on standard care with a history of flare-ups. Enrollment has started in the United States, with about 2,136 patients planned across 28 countries.
Confirmed
Global impact / market context
A successful Phase 3 trial could add a new use for Ohtuvayre, potentially supporting future revenue growth. Failure would mean lost research spending and delay. The trial also tests whether the drug helps patients whose symptoms persist despite current standard treatment.
Analyst inference
Merck is investing in a late-stage respiratory drug trial, which uses cash and takes years before any payoff. Investors weigh trial risk against the chance of a larger market for Ohtuvayre. Results timing and enrollment pace will shape expectations.
Analyst inference
What to watch
- Enrollment progress for ENHANCE-3, which plans about 2,136 patients in 28 countries, will indicate how quickly the trial can generate results. Confirmed
- Merck could report future updates on the primary endpoint, the yearly rate of moderate or severe COPD flare-ups, once the study advances. Proposed
- Watch whether Ohtuvayre shows a clear benefit over standard care, since that would support its broader use and potential sales growth. Analyst inference
Evidence
- Original source link unavailable